

ASX Market Announcements  
ASX Limited  
Level 4  
North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

**RE: Release of Restricted Securities from Escrow**

In connection with the quotation of Adherium Limited's fully paid ordinary shares (**Shares**) on the Australian Securities Exchange (**ASX**) on 26 August 2015 certain security holders in the Company were required to enter into ASX imposed restriction agreements and/or voluntary escrow agreements. These agreements restricted the relevant security holders from dealing in their securities for periods of up to 24 months from the date of quotation.

In accordance with ASX Listing Rule 3.10A, the Company advises that 146,870 fully paid ordinary shares of the Company will be released from ASX imposed restriction on 14 December 2015.

Application for quotation of these 146,870 fully paid ordinary shares will also be made following their release from restriction.

Kind regards



Rob Turnbull  
Joint Company Secretary

[ASX: ADR](#)

**ABN**

24 605 352 510

**Company Overview**

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

**Directors**

Dr J Doug Wilson (Chair)  
Mr Garth Sutherland (Group CEO)  
Prof. John Mills  
Mr Jeremy Curnock Cook  
Mr Bruce McHarrie  
Mr Bryan Mogridge

**Joint Company Secretaries**

Mr Rob Turnbull  
Ms Bronwyn Le Grice

**Registered Office**

Level 12, 15 William Street  
Melbourne VIC 3000  
Australia

**NZ Office**

Level 2, 204 Quay Street  
Auckland 1010  
New Zealand

**Investor Relations Contact**

Ms Bronwyn Le Grice  
+61 424 862 600

**Email**

[investors@adherium.com](mailto:investors@adherium.com)

**Website**

[www.adherium.com](http://www.adherium.com)